Stockreport

Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints [MarketWatch]

Cytokinetics, Incorporated  (CYTK) 
Last cytokinetics, incorporated earnings: 3/3 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytokinetics.com/investor-overview
PDF Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints Shares of biotech Cytokinetics Inc. CYTK, -3.50% plunged 19% in premarket trade Monda [Read more]